JP2018531218A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531218A5
JP2018531218A5 JP2018507641A JP2018507641A JP2018531218A5 JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5 JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5
Authority
JP
Japan
Prior art keywords
group
tautomer
pharmaceutically acceptable
acceptable salt
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018507641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531218A (ja
JP6898306B2 (ja
JP2018531218A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/092989 external-priority patent/WO2017024968A1/zh
Publication of JP2018531218A publication Critical patent/JP2018531218A/ja
Publication of JP2018531218A6 publication Critical patent/JP2018531218A6/ja
Publication of JP2018531218A5 publication Critical patent/JP2018531218A5/ja
Application granted granted Critical
Publication of JP6898306B2 publication Critical patent/JP6898306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018507641A 2015-08-07 2016-08-03 Fgfr及びvegfr阻害剤であるビニル化合物 Active JP6898306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510484124.6 2015-08-07
CN201510484124 2015-08-07
CN201510908082 2015-12-09
CN201510908082.4 2015-12-09
PCT/CN2016/092989 WO2017024968A1 (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Publications (4)

Publication Number Publication Date
JP2018531218A JP2018531218A (ja) 2018-10-25
JP2018531218A6 JP2018531218A6 (ja) 2018-12-13
JP2018531218A5 true JP2018531218A5 (enExample) 2019-09-19
JP6898306B2 JP6898306B2 (ja) 2021-07-07

Family

ID=57983012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507641A Active JP6898306B2 (ja) 2015-08-07 2016-08-03 Fgfr及びvegfr阻害剤であるビニル化合物

Country Status (5)

Country Link
US (1) US10519133B2 (enExample)
EP (1) EP3333157B1 (enExample)
JP (1) JP6898306B2 (enExample)
CN (1) CN107922349B (enExample)
WO (1) WO2017024968A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151126A1 (ja) * 2017-02-14 2018-08-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
US11078194B2 (en) 2017-12-07 2021-08-03 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
CN113490667B (zh) * 2018-12-29 2023-10-27 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
WO2020156564A1 (zh) 2019-02-02 2020-08-06 南京明德新药研发有限公司 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
AU2020214518B2 (en) * 2019-02-02 2022-12-15 Novaonco Js Therapeutics Co., Ltd. Fluorovinylbenzamide compound as PD-L1 immunomodulator
WO2020249096A1 (zh) * 2019-06-14 2020-12-17 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
WO2021088859A1 (zh) * 2019-11-06 2021-05-14 暨南大学 吲唑类化合物及其药用组合物和应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
EP4186894B1 (en) * 2020-08-11 2024-12-04 Henan Medinno Pharmaceutical Technology Co., Ltd. Fgfr inhibitor compound and use thereof
MX2023007162A (es) * 2020-12-17 2023-06-29 Blossomhill Therapeutics Inc Macrociclos y sus usos.
CN116761798A (zh) * 2020-12-30 2023-09-15 泰拉生物科学公司 作为激酶抑制剂的吲唑类化合物
PE20240687A1 (es) 2020-12-30 2024-04-10 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
US20240316022A1 (en) * 2021-06-30 2024-09-26 Tyra Biosciences, Inc. Indazole compounds
JP2025525433A (ja) * 2022-06-29 2025-08-05 タイラ・バイオサイエンシーズ・インコーポレイテッド インダゾール化合物
CN116239623B (zh) * 2022-11-18 2025-11-18 江西亚太科技发展有限公司 一种硼酸酯的制备方法及其应用
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
NZ524717A (en) 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン/スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
US20060058366A1 (en) * 2002-12-03 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
DK1585743T3 (da) * 2002-12-19 2007-09-17 Pfizer 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds

Similar Documents

Publication Publication Date Title
JP2018531218A5 (enExample)
KR102820455B1 (ko) Shp2 활성 억제용 화합물의 제조 방법
JP2019524883A5 (enExample)
JP2020169171A5 (enExample)
JP2006515858A5 (enExample)
CN113474343A (zh) 作为ret抑制剂的吡唑并吡啶类化合物及其应用
JP2017504576A5 (enExample)
JP2016121196A5 (enExample)
JP2018528261A5 (enExample)
JP2016515560A5 (enExample)
JP2020510091A5 (enExample)
JP2014503525A5 (enExample)
JP2014503574A5 (enExample)
JP2015532295A5 (enExample)
JP2020529994A5 (enExample)
JP2016504387A5 (enExample)
JP2016130266A5 (enExample)
JP2008505157A5 (enExample)
JP2020500869A5 (enExample)
JP2019535723A5 (enExample)
JP2020063289A5 (enExample)
JP2015511232A5 (enExample)
JP2020128426A5 (enExample)
JP2006509842A5 (enExample)
CN112771045A (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用